Ashley Gallagher

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.

Meanwhile, newly approved Cobenfy and the long-acting injectable antipsychotics may help with the long-standing problem of nonadherence to schizophrenia treatment.

Large PBMs are removing Humira from some of their formularies. AMCP Nexus panelists still see challenges and a need for education and more attention to patient interests.

Several companies are developing new drugs to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), a formerly obscure condition that is getting an increasing amount of attention.

Just a small percentage of employers use alternative funding programs, including accumulators and maximizers. But approximately 60% of employers who do use these programs said in a survey they are effective at managing healthcare costs.